Zacks Research Expects Lower Earnings for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Equities researchers at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Avanos Medical in a research note issued on Wednesday, March 19th. Zacks Research analyst R. Department now expects that the company will earn $0.30 per share for the quarter, down from their prior forecast of $0.43. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s FY2025 earnings at $1.20 EPS, Q2 2026 earnings at $0.30 EPS and FY2026 earnings at $1.48 EPS.

Separately, StockNews.com raised Avanos Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th.

Avanos Medical Stock Performance

Shares of NYSE:AVNS opened at $14.16 on Monday. Avanos Medical has a 12-month low of $14.12 and a 12-month high of $25.36. The company’s 50 day moving average price is $15.77 and its two-hundred day moving average price is $18.51. The firm has a market cap of $651.40 million, a PE ratio of 41.65 and a beta of 1.17. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The business had revenue of $179.60 million for the quarter, compared to analyst estimates of $177.23 million.

Hedge Funds Weigh In On Avanos Medical

Several hedge funds and other institutional investors have recently modified their holdings of AVNS. T. Rowe Price Investment Management Inc. lifted its position in shares of Avanos Medical by 27.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock worth $47,941,000 after buying an additional 644,267 shares during the last quarter. Tributary Capital Management LLC lifted its holdings in shares of Avanos Medical by 38.1% in the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock worth $14,217,000 after acquiring an additional 246,379 shares during the last quarter. Brown Advisory Inc. boosted its stake in shares of Avanos Medical by 12.0% in the 4th quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock valued at $30,329,000 after purchasing an additional 204,218 shares in the last quarter. D. E. Shaw & Co. Inc. grew its holdings in shares of Avanos Medical by 43.1% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock valued at $7,874,000 after purchasing an additional 148,902 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Avanos Medical by 189.8% during the 4th quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company’s stock valued at $3,210,000 after purchasing an additional 132,063 shares during the last quarter. Institutional investors own 95.17% of the company’s stock.

Insider Activity at Avanos Medical

In related news, SVP Kerr Holbrook sold 7,000 shares of Avanos Medical stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the transaction, the senior vice president now directly owns 82,047 shares of the company’s stock, valued at $1,251,216.75. This trade represents a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.90% of the stock is owned by insiders.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.